{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T21:29:13Z","timestamp":1715549353029},"reference-count":75,"publisher":"IntechOpen","isbn-type":[{"value":"9781839686207","type":"print"},{"value":"9781839686214","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:00:00Z","timestamp":1627430400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Multiple Myeloma (MM) is the most common malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. Clinical investigation of MM requires the evaluation of bone marrow for plasma cell infiltration, and detection and quantification of monoclonal protein in the serum or urine, and evidence for end-organ damage (i.e., hypercalcemia, renal insufficiency, anemia, or bone lesions). The overall goal of treatment of MM is to improve survival. The treatment landscape and clinical outcome of MM have changed in the last two decades, with an improved median survival of 8\u201310\u00a0years. Management of MM involves induction, consolidation, and maintenance therapy. Currently, Autologous stem cell transplant (ASCT) is considered as the standard care of treatment for newly diagnosed fit MM patients. Multiple combinations of proteasome inhibitors (PIs) and immunomodulatory drugs (IMIDs) such as Thalidomide, lenalidomide, and pomalidomide have been under evaluation in ASCT-eligible and ineligible settings, and studies are still ongoing. For patients with ASCT-eligible newly diagnosed MM, induction therapy with triple drugs should contain an IMiD, a PI, and a corticosteroid, usually lenalidomide-bortezomib-dexamethasone. For ASCT-ineligible patients on lenalidomide with dexamethasone (Rd), with addition of bortezomib or daratumumab can be considered.<\/jats:p>","DOI":"10.5772\/intechopen.97390","type":"book-chapter","created":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T06:45:45Z","timestamp":1620974745000},"source":"Crossref","is-referenced-by-count":1,"title":["Treatment Approaches of Multiple Myeloma"],"prefix":"10.5772","author":[{"given":"Minyahil","family":"Alebachew Woldu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atalay","family":"Mulu Fentie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamrat","family":"Assefa Tadesse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3774","published-online":{"date-parts":[[2021,7,28]]},"reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, et al. Multiple myeloma, version 3.2017, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2017;15(2):230-69. doi: https:\/\/doi.org\/10.6004\/jnccn.2017.0023","DOI":"10.6004\/jnccn.2017.0023"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Kuehl WM, Bergsagel PL. Early genetic events provide the basis for a clinical classification of multiple myeloma. ASH Education Program Book. 2005;2005(1):346-52. doi: https:\/\/doi.org\/10.1182\/asheducation-2005.1.346","DOI":"10.1182\/asheducation-2005.1.346"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Willrich MA, Katzmann JA. Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias. Clinical Chemistry and Laboratory Medicine (CCLM). 2016;54(6):907-19. doi: https:\/\/doi.org\/10.1515\/cclm-2015-0580","DOI":"10.1515\/cclm-2015-0580"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Harousseau J-L, Dreyling M. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2010;21:v155-v1v7. doi: 10.1093\/annonc\/mdq178","DOI":"10.1093\/annonc\/mdq178"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Moreau P, San Miguel J, Ludwig H, Schouten H, Mohty M, Dimopoulos M, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2013;24:vi133-vi7. doi: 10.1093\/annonc\/mdt297","DOI":"10.1093\/annonc\/mdt297"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. American journal of hematology. 2016;91(7):719-734. doi: 10.1002\/ajh.24402","DOI":"10.1002\/ajh.24402"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, et al. European Myeloma Network guidelines for the management of multiple myeloma-related complications. Haematologica. 2015;100(10):1254-1266. doi: 10.3324\/haematol.2014.117176","DOI":"10.3324\/haematol.2014.117176"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Terpos E, Engelhardt M, Cook G, Gay F, Mateos M-V, Ntanasis-Stathopoulos I, et al. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia. 2020;34(8):2000-11. doi: https:\/\/doi.org\/10.1038\/s41375-020-0876-z","DOI":"10.1038\/s41375-020-0876-z"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Gay F, Engelhardt M, Terpos E, W\u00e4sch R, Giaccone L, Auner HW, et al. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica. 2018;103(2):197. doi: 10.3324\/haematol.2017.174573","DOI":"10.3324\/haematol.2017.174573"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. American journal of hematology. 2020;95(5):548-67. doi: https:\/\/doi.org\/10.1002\/ajh.25791","DOI":"10.1002\/ajh.25791"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"San-Miguel JF, Paiva B, Guti\u00e9rrez NC. New tools for diagnosis and monitoring of multiple myeloma. Am Soc Clin Oncol Educ Book. 2013;10:12-15","DOI":"10.14694\/EdBook_AM.2013.33.e313"},{"key":"ref=12","unstructured":"Fowler NH, Staudt LM, Bradner J. Hot Pathways for Targeted Therapy of B-Cell Malignancies. American Society of Clinical Oncology Educational Book. 2013"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The lancet oncology. 2014;15(12):e538-e48. doi: https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Lentzsch S, O'Sullivan A, Kennedy RC, Abbas M, Dai L, Pregja SL, et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1\/2 open-label, dose escalation study. Blood, The Journal of the American Society of Hematology. 2012;119(20):4608-13. doi: https:\/\/doi.org\/10.1182\/blood-2011-12-395715","DOI":"10.1182\/blood-2011-12-395715"},{"key":"ref=15","unstructured":"Davidson HC. Serotonin is a survival factor for human multiple myeloma cells. Drexel University College of Medicine; 2004"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Durie BG. Role of new treatment approaches in defining treatment goals in multiple myeloma\u2013the ultimate goal is extended survival. Cancer treatment reviews. 2010;36:S18-S23. doi: https:\/\/doi.org\/10.1016\/S0305-7372(10)70008-6","DOI":"10.1016\/S0305-7372(10)70008-6"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Chim C, Kumar S, Orlowski R, Cook G, Richardson P, Gertz M, et al. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia. 2018;32(2):252-262","DOI":"10.1038\/leu.2017.329"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Cetani G, Boccadoro M, Oliva S. A look at treatment strategies for relapsed multiple myeloma. Expert review of anticancer therapy. 2018;18(8):735-50. doi: https:\/\/doi.org\/10.1080\/14737140.2018.1477594","DOI":"10.1080\/14737140.2018.1477594"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood cancer journal. 2020;10(9):1-10","DOI":"10.1038\/s41408-020-00359-2"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Bagal B, Bonda A. Induction therapy in newly diagnosed multiple myeloma: Current research scenario and questions for the future. Cancer Research, Statistics, and Treatment. 2019;2(1):76. doi: 10.4103\/CRST.CRST_42_19","DOI":"10.4103\/CRST.CRST_42_19"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Paul B, Lipe B, Ocio EM, Usmani SZ. Induction therapy for newly diagnosed multiple myeloma. American Society of Clinical Oncology Educational Book. 2019;39:e176-ee86. doi: 10.1200\/EDBK_238527","DOI":"10.1200\/EDBK_238527"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"Chari A, Parikh K, Ni Q\u2009, Abouzaid S. Treatment patterns and clinical and economic outcomes in patients with newly diagnosed multiple myeloma treated with lenalidomide-and\/or bortezomib-containing regimens without stem cell transplant in a real-world setting. Clinical Lymphoma Myeloma and Leukemia. 2019;19(10):645-55. doi: https:\/\/doi.org\/10.1016\/j.clml.2019.06.007","DOI":"10.1016\/j.clml.2019.06.007"},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. The lancet oncology. 2011;12(5):431-40. doi: https:\/\/doi.org\/10.1016\/S1470-2045(11)70081-X","DOI":"10.1016\/S1470-2045(11)70081-X"},{"key":"ref=24","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Jakubowiak AJ, McCarthy PL, Orlowski RZ, Attal M, Blad\u00e9 J, et al. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood cancer journal. 2020;10(2):1-19. doi: https:\/\/doi.org\/10.1038\/s41408-020-0273-x","DOI":"10.1038\/s41408-020-0273-x"},{"key":"ref=25","doi-asserted-by":"crossref","unstructured":"Goldschmidt H, Ashcroft J, Szabo Z, Garderet L. Navigating the treatment landscape in multiple myeloma: which combinations to use and when? Annals of hematology. 2019;98(1):1-18. doi: https:\/\/doi.org\/10.1007\/s00277-018-3546-8","DOI":"10.1007\/s00277-018-3546-8"},{"key":"ref=26","doi-asserted-by":"crossref","unstructured":"Cohen YC, Zada M, Gatt ME, Lavi N, Ganzel C, Wang S-Y, et al. Kydar multicenter trial of quadruple regimen for induction resistant myeloma combined with translational single-cell analysis identifies potential drivers of advanced resistance, including novel immune checkpoints. American Society of Hematology Washington, DC; 2019","DOI":"10.1182\/blood-2019-129618"},{"key":"ref=27","doi-asserted-by":"crossref","unstructured":"Branagan A, Lei M, Lou U, Raje N. Current Treatment Strategies for Multiple Myeloma. JCO Oncology Practice. 2020;16(1):5-14. doi: 10.1200\/jop.19.00244","DOI":"10.1200\/JOP.19.00244"},{"key":"ref=28","doi-asserted-by":"crossref","unstructured":"Leclercq R, Courvalin P. Resistance to glycopeptides in enterococci. Clinical Infectious Diseases. 1997;24(4):545-554","DOI":"10.1093\/clind\/24.4.545"},{"key":"ref=29","doi-asserted-by":"crossref","unstructured":"Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, et al. Autologous transplantation and maintenance therapy in multiple myeloma. New England Journal of Medicine. 2014;371(10):895-905","DOI":"10.1056\/NEJMoa1402888"},{"key":"ref=30","doi-asserted-by":"crossref","unstructured":"Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123(23):3664-71. doi: https:\/\/doi.org\/10.1182\/blood-2014-01-552984","DOI":"10.1182\/blood-2014-01-552984"},{"key":"ref=31","doi-asserted-by":"crossref","unstructured":"Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Blad\u00e9 J, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011;117(23):6063-6073","DOI":"10.1182\/blood-2011-02-297325"},{"key":"ref=32","doi-asserted-by":"crossref","unstructured":"Sivaraj D, Green MM, Li Z, Sung AD, Sarantopoulos S, Kang Y, et al. Outcomes of maintenance therapy with bortezomib after autologous stem cell transplantation for patients with multiple myeloma. Biology of Blood and Marrow Transplantation. 2017;23(2):262-8. doi: https:\/\/doi.org\/10.1016\/j.bbmt.2016.11.010","DOI":"10.1016\/j.bbmt.2016.11.010"},{"key":"ref=33","doi-asserted-by":"crossref","unstructured":"Ludwig H, Durie BG, McCarthy P, Palumbo A, San Miguel J, Barlogie B, et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood. 2012;119(13):3003-15. doi: ttps:\/\/doi.org\/10.1182\/blood-2011-11-374249","DOI":"10.1182\/blood-2011-11-374249"},{"key":"ref=34","doi-asserted-by":"crossref","unstructured":"Engelhardt M, Terpos E, Kleber M, Gay F, W\u00e4sch R, Morgan G, et al. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. haematologica. 2014;99(2):232. doi: doi: 10.3324\/haematol.2013.099358","DOI":"10.3324\/haematol.2013.099358"},{"key":"ref=35","doi-asserted-by":"crossref","unstructured":"Kapoor P, Ramakrishnan V, Rajkumar SV. Bortezomib combination therapy in multiple myeloma. Seminars in hematology: Elsevier; 2012. p. 228-242","DOI":"10.1053\/j.seminhematol.2012.04.010"},{"key":"ref=36","doi-asserted-by":"crossref","unstructured":"Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. The Journal of Pain. 2009;10(2):113-30. e22. doi: https:\/\/doi.org\/10.1016\/j.jpain.2008.10.008","DOI":"10.1016\/j.jpain.2008.10.008"},{"key":"ref=37","doi-asserted-by":"crossref","unstructured":"Dhakal B, Szabo A, Chhabra S, Hamadani M, D\u2019Souza A, Usmani SZ, et al. Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis. JAMA oncology. 2018;4(3):343-350. doi: 10.1001\/jamaoncol.2017.4600","DOI":"10.1001\/jamaoncol.2017.4600"},{"key":"ref=38","doi-asserted-by":"crossref","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955-62. doi: https:\/\/doi.org\/10.1182\/blood-2016-01-631200","DOI":"10.1182\/blood-2016-01-631200"},{"key":"ref=39","doi-asserted-by":"crossref","unstructured":"Wang Y, Yang F, Shen Y, Zhang W, Wang J, Chang VT, et al. Maintenance therapy with immunomodulatory drugs in multiple myeloma: a meta-analysis and systematic review. Journal of the National Cancer Institute. 2016;108(3):djv342. doi: https:\/\/doi.org\/10.1093\/jnci\/djv342","DOI":"10.1093\/jnci\/djv342"},{"key":"ref=40","doi-asserted-by":"crossref","unstructured":"Warsame R, Kumar SK, Gertz M, Lacy M, Buadi F, Hayman S, et al. Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. Blood cancer journal. 2015;5(5):e310-e. doi: https:\/\/doi.org\/10.1038\/bcj.2015.34","DOI":"10.1038\/bcj.2015.34"},{"key":"ref=41","doi-asserted-by":"crossref","unstructured":"Hanbali A, Hassanein M, Rasheed W, Aljurf M, Alsharif F. The evolution of prognostic factors in multiple myeloma. Advances in hematology. 2017;2017. doi: https:\/\/doi.org\/10.1155\/2017\/4812637","DOI":"10.1155\/2017\/4812637"},{"key":"ref=42","doi-asserted-by":"crossref","unstructured":"Moreau P. How I treat myeloma with new agents. Blood. 2017;130(13):1507-13. doi: https:\/\/doi.org\/10.1182\/blood-2017-05-743203","DOI":"10.1182\/blood-2017-05-743203"},{"key":"ref=43","doi-asserted-by":"crossref","unstructured":"Nijhof IS, van de Donk NW, Zweegman S, Lokhorst HM. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update. Drugs. 2018;78(1):19-37","DOI":"10.1007\/s40265-017-0841-y"},{"key":"ref=44","doi-asserted-by":"crossref","unstructured":"Chung C. Role of immunotherapy in targeting the bone marrow microenvironment in multiple myeloma: an evolving therapeutic strategy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2017;37(1):129-143","DOI":"10.1002\/phar.1871"},{"key":"ref=45","doi-asserted-by":"crossref","unstructured":"Raza S, Safyan RA, Rosenbaum E, Bowman AS, Lentzsch S. Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist. Therapeutic advances in hematology. 2017;8(2):55-70","DOI":"10.1177\/2040620716680548"},{"key":"ref=46","doi-asserted-by":"crossref","unstructured":"Rajkumar SV. Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. American journal of hematology. 2018;93(8):1091-1110","DOI":"10.1002\/ajh.25117"},{"key":"ref=47","doi-asserted-by":"crossref","unstructured":"Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood, The Journal of the American Society of Hematology. 2014;123(12):1826-1832","DOI":"10.1182\/blood-2014-04-566661"},{"key":"ref=48","doi-asserted-by":"crossref","unstructured":"Ziogas DC, Dimopoulos MA, Kastritis E. Prognostic factors for multiple myeloma in the era of novel therapies. Expert review of hematology. 2018;11(11):863-879","DOI":"10.1080\/17474086.2018.1537776"},{"key":"ref=49","unstructured":"Lei M, Kim EB, Branagan A, Lou U, Zemel M, Raje N. Current management and emerging treatment strategies for multiple myeloma. Rinsho Ketsueki. 2019;60(9):1243-1256"},{"key":"ref=50","doi-asserted-by":"crossref","unstructured":"Dingli D, Ailawadhi S, Bergsagel PL, Buadi FK, Dispenzieri A, Fonseca R, et al. Therapy for relapsed multiple myeloma: guidelines from the Mayo stratification for myeloma and risk-adapted therapy. Mayo Clinic Proceedings: Elsevier; 2017. p. 578-598","DOI":"10.1016\/j.mayocp.2017.01.003"},{"key":"ref=51","doi-asserted-by":"crossref","unstructured":"Mukherjee D, Mukherjee KK. A Review on Therapeutic strategies of Relapsed and Refractory Multiple Myeloma. 2021","DOI":"10.31219\/osf.io\/bfj4z"},{"key":"ref=52","doi-asserted-by":"crossref","unstructured":"Moreau P, Zamagni E, Mateos M-V. Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide. Blood cancer journal. 2019;9(4):1-8","DOI":"10.1038\/s41408-019-0200-1"},{"key":"ref=53","doi-asserted-by":"crossref","unstructured":"Coleman R, Brown J, Terpos E, Lipton A, Smith MR, Cook R, et al. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer treatment reviews. 2008;34(7):629-639","DOI":"10.1016\/j.ctrv.2008.05.001"},{"key":"ref=54","doi-asserted-by":"crossref","unstructured":"Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, et al. European Myeloma Network guidelines for the management of multiple myeloma-related complications. haematologica. 2015;100(10):1254","DOI":"10.3324\/haematol.2014.117176"},{"key":"ref=55","doi-asserted-by":"crossref","unstructured":"Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. The Lancet. 2010;376(9757):1989-1999","DOI":"10.1016\/S0140-6736(10)62051-X"},{"key":"ref=56","doi-asserted-by":"crossref","unstructured":"Beir\u00e3o I, Costa PP. Erythropoietin in Familial Amyloidosis ATTR V30M. Erythropoietic Stimulating Agents. 2013;1:1144","DOI":"10.2174\/9781608057474113010012"},{"key":"ref=57","doi-asserted-by":"crossref","unstructured":"Talmadge JE. Natural product derived immune-regulatory agents. International immunopharmacology. 2016;37:5-15","DOI":"10.1016\/j.intimp.2016.02.025"},{"key":"ref=58","unstructured":"Beguin Y, Dujardin C, Piron M, Vanstraelen G. Treatment of anaemia with erythropoietin. ESH Scientific Updates Disorders of Iron Homeostasis, Erythrocytes and erythropoiesis. 2006:180-209"},{"key":"ref=59","unstructured":"Westerink MJ, Schroeder Jr HW, Nahm MH. Immune responses to pneumococcal vaccines in children and adults: rationale for age-specific vaccination. Aging and disease. 2012;3(1):51"},{"key":"ref=60","doi-asserted-by":"crossref","unstructured":"Beksa\u00e7 M. European myeloma network guidelines for the management of multiple myeloma-related complications. 2015. doi: https:\/\/doi.org\/10.3324\/haematol.2014.117176","DOI":"10.3324\/haematol.2014.117176"},{"key":"ref=61","doi-asserted-by":"crossref","unstructured":"Nahi H, Chrobok M, Gran C, Lund J, Gruber A, Gahrton G, et al. Infectious complications and NK cell depletion following daratumumab treatment of multiple myeloma. PloS one. 2019;14(2):e0211927. doi: https:\/\/doi.org\/10.1371\/journal.pone.0211927","DOI":"10.1371\/journal.pone.0211927"},{"key":"ref=62","doi-asserted-by":"crossref","unstructured":"Ludwig H, Boccadoro M, Moreau P, San-Miguel J, Cavo M, Pawlyn C, et al. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia. 2020:1-14","DOI":"10.1038\/s41375-020-01016-0"},{"key":"ref=63","doi-asserted-by":"crossref","unstructured":"Palumbo A, Sezer O, Kyle R, Miguel J, Orlowski R, Moreau P, et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia. 2009;23(10):1716-30. doi: https:\/\/doi.org\/10.1038\/leu.2009.122","DOI":"10.1038\/leu.2009.122"},{"key":"ref=64","doi-asserted-by":"crossref","unstructured":"Moreau P, San Miguel J, Sonneveld P, Mateos M-V, Zamagni E, Avet-Loiseau H, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2017;28:iv52-iv61. doi: 10.1200\/JCO.2016.70.4320","DOI":"10.1093\/annonc\/mdx096"},{"key":"ref=65","doi-asserted-by":"crossref","unstructured":"Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. Journal of Clinical Oncology. 2017;35(8):826. doi: 10.1200\/JCO.2016.70.4320","DOI":"10.1200\/JCO.2017.35.15_suppl.e19041"},{"key":"ref=66","doi-asserted-by":"crossref","unstructured":"Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D\u2019Rozario J, Assouline S, et al. Venetoclax\u2013rituximab in relapsed or refractory chronic lymphocytic leukemia. New England Journal of Medicine. 2018;378(12):1107-1120. doi: 10.1056\/NEJMoa1713976","DOI":"10.1056\/NEJMoa1713976"},{"key":"ref=67","doi-asserted-by":"crossref","unstructured":"Wudhikarn K, Wills B, Lesokhin AM. Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action. Best Practice & Research Clinical Haematology. 2020;33(1):101143. doi: https:\/\/doi.org\/10.1016\/j.beha.2020.101143","DOI":"10.1016\/j.beha.2020.101143"},{"key":"ref=68","doi-asserted-by":"crossref","unstructured":"Saturni S, Bellini F, Braido F, Paggiaro P, Sanduzzi A, Scichilone N, et al. Randomized controlled trials and real life studies. Approaches and methodologies: a clinical point of view. Pulmonary pharmacology & therapeutics. 2014;27(2):129-38. doi: https:\/\/doi.org\/10.1016\/j.pupt.2014.01.005","DOI":"10.1016\/j.pupt.2014.01.005"},{"key":"ref=69","unstructured":"Domingo E, Schwartz Jr S. BRAF (v-raf murine sarcoma viral oncogene homolog B1. Atlas of Genetics and Cytogenetics in Oncology and Haematology. 2004"},{"key":"ref=70","doi-asserted-by":"crossref","unstructured":"Lee S-T, Kim SW, Ki C-S, Jang J-H, Shin JH, Oh YL, et al. Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area. The Journal of Clinical Endocrinology & Metabolism. 2012;97(7):2299-306. doi: https:\/\/doi.org\/10.1210\/jc.2011-3135","DOI":"10.1210\/jc.2011-3135"},{"key":"ref=71","doi-asserted-by":"crossref","unstructured":"Baik CS, Myall NJ, Wakelee HA. Targeting BRAF-mutant non-small cell lung cancer: From molecular profiling to rationally designed therapy. The oncologist. 2017;22(7):786. doi: 10.1634\/theoncologist.2016-0458","DOI":"10.1634\/theoncologist.2016-0458"},{"key":"ref=72","doi-asserted-by":"crossref","unstructured":"van de Donk NW, Janmaat ML, Mutis T, Lammerts van Bueren JJ, Ahmadi T, Sasser AK, et al. Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond. Immunological reviews. 2016;270(1):95-112. doi: https:\/\/doi.org\/10.1111\/imr.12389","DOI":"10.1111\/imr.12389"},{"key":"ref=73","doi-asserted-by":"crossref","unstructured":"Cavo M. Facing lenalidomide-refractory myeloma. Blood, The Journal of the American Society of Hematology. 2019;134(2):99-101. doi: https:\/\/doi.org\/10.1182\/blood-2019-04-901157","DOI":"10.1182\/blood-2019-04-901157"},{"key":"ref=74","doi-asserted-by":"crossref","unstructured":"Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34(4):985-1005. doi: https:\/\/doi.org\/10.1038\/s41375-020-0734-z","DOI":"10.1038\/s41375-020-0734-z"},{"key":"ref=75","doi-asserted-by":"crossref","unstructured":"Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunology and cell biology. 2015;93(3):290-6. doi: https:\/\/doi.org\/10.1038\/icb.2014.93","DOI":"10.1038\/icb.2014.93"}],"container-title":["Multiple Myeloma"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.intechopen.com\/download\/pdf\/76632","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T09:30:58Z","timestamp":1672133458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.intechopen.com\/books\/multiple-myeloma\/treatment-approaches-of-multiple-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,28]]},"ISBN":["9781839686207","9781839686214"],"references-count":75,"URL":"https:\/\/doi.org\/10.5772\/intechopen.97390","relation":{},"subject":[],"published":{"date-parts":[[2021,7,28]]}}}